VANSIL Drug Patent Profile

Which patents cover Vansil, and what generic alternatives are available?

Vansil is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in VANSIL is oxamniquine. Additional details are available on the oxamniquine profile page.

Summary for VANSIL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	35
Patent Applications:	1,671
DailyMed Link:	VANSIL at DailyMed

US Patents and Regulatory Information for VANSIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	VANSIL	oxamniquine	CAPSULE;ORAL	018069-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for VANSIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	VANSIL	oxamniquine	CAPSULE;ORAL	018069-001	Approved Prior to Jan 1, 1982	3,821,228
Pfizer	VANSIL	oxamniquine	CAPSULE;ORAL	018069-001	Approved Prior to Jan 1, 1982	3,925,391
Pfizer	VANSIL	oxamniquine	CAPSULE;ORAL	018069-001	Approved Prior to Jan 1, 1982	3,903,283

International Patents for VANSIL

See the table below for patents covering VANSIL around the world.

Country	Patent Number	Title	Estimated Expiration
Netherlands	6808151
Netherlands	155008
Belgium	762071

VANSIL Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for VANSIL (Oxamniquine)

Introduction

VANSIL, known generically as oxamniquine, is a medication used to treat schistosomiasis, a parasitic infection caused by the Schistosoma mansoni parasite. Here, we delve into the market dynamics and financial trajectory of this drug, exploring its current market status, future projections, and the factors influencing its use.

Market Size and Growth

The schistosomiasis drugs market, which includes VANSIL, was valued at USD 70.4 million in 2021. This market is forecasted to grow at a Compound Annual Growth Rate (CAGR) of 3.8% from 2024 to 2031[1].

Key Players

The market for schistosomiasis drugs is characterized by a few key players, with pharmaceutical companies like Pfizer, which originally developed and marketed VANSIL, playing significant roles. Other companies involved in the development and distribution of schistosomiasis treatments also contribute to the market dynamics[1].

Drug Characteristics and Efficacy

Oxamniquine, sold under the brand name VANSIL, is an anthelmintic with specific efficacy against Schistosoma mansoni. It works by causing paralysis of the parasitic worms, leading to their detachment from the host's blood vessels and eventual death. Despite its effectiveness, oxamniquine is often less preferred compared to praziquantel due to its higher cost and specific indications[4].

Market Competition

The generic drug market, including that for schistosomiasis treatments, is influenced by the number of competitors. Generic drug prices tend to fall as the number of competitors increases, approaching long-run marginal costs when there are eight or more competitors. This dynamic can affect the pricing and profitability of VANSIL, especially if generic versions become more prevalent[3].

Regulatory Environment

Regulatory changes can significantly impact the market dynamics of drugs like VANSIL. For instance, increased scrutiny by regulatory bodies like the FDA can raise the costs of obtaining approval for generic drugs, potentially reducing competition and affecting prices. Conversely, policies that facilitate simultaneous approval of multiple generic entrants can lead to earlier competition and lower prices[3].

Geographic Distribution

VANSIL is not commercially available in the United States but is used in various tropical and subtropical regions where schistosomiasis is prevalent. The drug's availability and market size are heavily influenced by public health initiatives and government programs aimed at controlling and eliminating schistosomiasis in these regions[4].

Financial Projections

Given the forecasted growth rate of the schistosomiasis drugs market, VANSIL is expected to contribute to this growth, albeit with potential challenges from generic competition and the preference for praziquantel. The market is projected to reach a significant value by 2031, driven by increasing awareness, public health efforts, and the need for effective treatments in endemic areas[1].

Pricing and Cost Considerations

Oxamniquine is more expensive than praziquantel, which can affect its market share. The cost of treatment with VANSIL, combined with the availability of cheaper alternatives, influences its financial trajectory. Public health programs often opt for the more cost-effective praziquantel, which can limit the market share of VANSIL[4].

Side Effects and Safety Profile

The safety profile of VANSIL, including side effects such as sleepiness, headache, nausea, diarrhea, and reddish urine, can impact patient compliance and market acceptance. Seizures in individuals with epilepsy are a significant concern, necessitating careful patient selection and monitoring[4].

Public Health Impact

VANSIL's role in public health initiatives is crucial, especially in regions where schistosomiasis is a significant health concern. Its inclusion in the World Health Organization's List of Essential Medicines underscores its importance in global health strategies[4].

Future Trends

The future market for VANSIL will be shaped by several factors, including advancements in treatment options, changes in regulatory policies, and the ongoing battle against schistosomiasis. As public health efforts continue to focus on eliminating this disease, the demand for effective treatments like VANSIL is likely to remain steady, albeit with potential fluctuations based on market dynamics and competition.

Key Takeaways

• Market Growth: The schistosomiasis drugs market, including VANSIL, is expected to grow at a CAGR of 3.8% from 2024 to 2031.
• Competition: Generic competition and the preference for praziquantel can impact VANSIL's market share.
• Regulatory Environment: Changes in regulatory policies can affect the cost and availability of VANSIL.
• Geographic Distribution: VANSIL is primarily used in tropical and subtropical regions where schistosomiasis is prevalent.
• Financial Projections: The market is projected to reach a significant value by 2031, driven by public health efforts and the need for effective treatments.

FAQs

What is the current market size of the schistosomiasis drugs market?

The schistosomiasis drugs market was valued at USD 70.4 million in 2021[1].

Who are the key players in the schistosomiasis drugs market?

Key players include pharmaceutical companies like Pfizer, which originally developed and marketed VANSIL[1].

How does VANSIL work against schistosomiasis?

VANSIL works by causing paralysis of the Schistosoma mansoni worms, leading to their detachment from the host's blood vessels and eventual death[4].

Why is praziquantel often preferred over VANSIL?

Praziquantel is often preferred due to its lower cost and broader efficacy against different species of Schistosoma[4].

Is VANSIL available in the United States?

No, VANSIL is not commercially available in the United States[4].

Sources

1. Datam Intelligence: Schistosomiasis Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031)
2. Inxight Drugs: OXAMNIQUINE
3. Federal Trade Commission: Generic Drug Industry Dynamics
4. Wikipedia: Oxamniquine
5. PubMed: Shifting drug markets in North America - a global crisis in the making?